Kostekci Yasemin Ezgi, Okulu Emel, Bakirarar Batuhan, Kraja Elvis, Erdeve Omer, Atasay Begum, Arsan Saadet
Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey.
Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey.
Front Pediatr. 2022 Apr 25;10:870125. doi: 10.3389/fped.2022.870125. eCollection 2022.
Non-invasive respiratory support strategies are known to reduce the complications of invasive mechanical ventilation in preterm infants. Nasal continuous positive airway pressure (NCPAP) and nasal intermittent positive pressure ventilation (NIPPV) are commonly used ones. The recent meta-analyses indicated that early NIPPV did appear to be superior to NCPAP for decreasing respiratory failure and the need for intubation among preterm infants with respiratory distress syndrome (RDS). The aim of the study was to compare the short-term outcomes of extremely preterm infants who received NCPAP or NIPPV as an initial treatment of RDS.
This retrospective study included infants born before 29 weeks' gestation between 1 January 2018 and 31 December 2021 who received non-invasive respiratory support with NCPAP or NIPPV. For every infant included in the cohort, only the first episode of NCPAP or NIPPV as initial treatment was evaluated. The primary outcome was the need for intubation within 72 h, and the secondary outcomes were the need for intubation within 7 days, administration of surfactant, prematurity-related morbidities, mortality, and death or bronchopulmonary dysplasia (BPD).
During the study period, there were 116 inborn admissions of preterm infants born <29 weeks' gestation and 60 of them met the inclusion criteria. Of these, 31 (52%) infants received NCPAP while 29 (48%) infants received NIPPV at the first hours after birth. There were no differences in the baseline demographics between the groups ( > 0.05). Blood gas parameters (pH, pCO, HCO3, and lactate) at admission were not different. The need for intubation within 72 h as the primary outcome was similar between NCPAP and NIPPV groups (35.5 vs. 34.5%, = 0.935). The rates of surfactant requirement, need for intubation within 7 days, prematurity-related morbidities, mortality, and death/BPD were similar among the groups ( > 0.05).
Nasal intermittent positive pressure ventilation is non-inferior to NCPAP as an initial treatment in extremely preterm infants with RDS. Although the rate of intubation in the first week, mortality, and BPD did not differ between groups, additional studies are needed and the synchronization of NIPPV should be evaluated.
已知无创呼吸支持策略可减少早产儿有创机械通气的并发症。鼻持续气道正压通气(NCPAP)和鼻间歇正压通气(NIPPV)是常用的方法。最近的荟萃分析表明,对于患有呼吸窘迫综合征(RDS)的早产儿,早期NIPPV在降低呼吸衰竭和插管需求方面似乎优于NCPAP。本研究的目的是比较接受NCPAP或NIPPV作为RDS初始治疗的极早产儿的短期结局。
这项回顾性研究纳入了2018年1月1日至2021年12月31日期间出生孕周小于29周且接受NCPAP或NIPPV无创呼吸支持的婴儿。对于队列中纳入的每个婴儿,仅评估首次使用NCPAP或NIPPV作为初始治疗的情况。主要结局是72小时内的插管需求,次要结局是7天内的插管需求、表面活性剂的使用、早产相关疾病、死亡率以及死亡或支气管肺发育不良(BPD)。
在研究期间,有116例孕周小于29周的早产儿入院,其中60例符合纳入标准。其中,31例(52%)婴儿在出生后的头几个小时接受了NCPAP,29例(48%)婴儿接受了NIPPV。两组之间的基线人口统计学特征无差异(>0.05)。入院时的血气参数(pH、pCO、HCO3和乳酸)无差异。作为主要结局的72小时内插管需求在NCPAP组和NIPPV组之间相似(35.5%对34.5%,P=0.935)。各组之间表面活性剂需求率、7天内插管需求率、早产相关疾病、死亡率以及死亡/BPD发生率相似(>0.05)。
对于患有RDS的极早产儿,鼻间歇正压通气作为初始治疗并不劣于NCPAP。尽管两组在第一周的插管率、死亡率和BPD方面没有差异,但仍需要进一步研究并评估NIPPV的同步性。